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Activation of transcription can occur by the facilitated recruitment of TFIID to promoters by gene-speciﬁc
activators. To investigate the role of TFIIA in TFIID recruitment in vivo, we exploited a class of yeast
TATA-binding protein (TBP) mutants that is activation and DNA binding defective. We found that co-
overexpression of TOA1 and TOA2, the genes that encode yeast TFIIA, overcomes the activation defects caused
by the TBP mutants. Using a genetic screen, we isolated a new class of TFIIA mutants and identiﬁed three
regions on TFIIA that are likely to be involved in TBP recruitment or stabilization of the TBP-TATA complex
in vivo. Amino acid replacements in only one of these regions enhance TFIIA-TBP-DNA complex formation in
vitro, suggesting that the other regions are involved in regulatory interactions. To determine the relative
importance of TFIIA in the regulation of different genes, we constructed yeast strains to conditionally deplete
TFIIA levels prior to gene activation. While the activation of certain genes, such as INO1, was dramatically
impaired by TFIIA depletion, activation of other genes, such as CUP1, was unaffected. These data suggest that
TFIIA facilitates DNA binding by TBP in vivo, that TFIIA may be regulated by factors that target distinct
regions of the protein, and that promoters vary signiﬁcantly in the degree to which they require TFIIA for
activation.
Initiation of mRNA synthesis in eukaryotes depends upon
the controlled and coordinated activities of a large number of
proteins. RNA polymerase II and six different general tran-
scription factors (TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and
TFIIH) assemble into a transcriptionally competent preinitia-
tion complex (PIC) at the core promoter elements of class II
genes (47). Among the general transcription factors, TFIID
plays a central role in initiation as it binds speciﬁcally to the
TATA box through its component TATA-binding protein
(TBP) and nucleates PIC assembly (47). Gene-speciﬁc tran-
scriptional regulators typically bind upstream of the TATA box
and, in concert with coactivators and corepressors, modulate
the level of initiation by affecting the assembly or activity of the
PIC. Although any step in the initiation reaction potentially
may be regulated by the gene-speciﬁc factors, a growing body
of data suggests that some transcriptional activators enhance
the rate of initiation by recruiting TFIID to the core promoter
or by recruiting the RNA polymerase II holoenzyme to the
nascent PIC (20, 54, 65).
The importance of the TFIID recruitment step in gene reg-
ulation is supported by both genetic and biochemical studies.
In the yeast Saccharomyces cerevisiae, the rate-limiting associ-
ation of TBP with the TATA box can be accelerated by the
acidic activator Gcn4 (32), and artiﬁcial recruitment of TBP via
a heterologous DNA-binding domain can bypass the require-
ment for upstream activators (8, 31, 75). Two independent
genetic screens for TBP mutants that exhibit transcription ac-
tivation defects in vivo uncovered mutants with signiﬁcantly
reduced afﬁnity for DNA in vitro (3, 37). More recently, anal-
ysis of transcription initiation and PIC assembly on immobi-
lized DNA templates in yeast nuclear extracts showed that two
different acidic activators can facilitate TFIID recruitment
(56). In agreement with these studies of yeast, biochemical
studies performed with puriﬁed mammalian and viral tran-
scription factors have demonstrated activator-mediated en-
hancement of TFIID binding to TATA elements (38, 71) in a
manner that leads to a stable conformation change in the
developing PIC (9). Activator function in these assays is criti-
cally dependent upon the presence of TFIIA and the TBP-
associated factors (TAFs), which, together with TBP, comprise
TFIID.
TFIIA has multiple roles in RNA polymerase II transcrip-
tion. In agreement with its description as an RNA polymerase
II general transcription factor, TFIIA is required for basal
transcription in reaction mixtures containing TFIID (12, 51,
69, 76). However, TFIIA does not stimulate basal transcription
when TFIID is replaced with TBP (41, 59, 69), even though
TFIIA can increase the afﬁnity of TBP for TATA elements in
vitro (25, 36, 72, 77). In addition to its involvement in basal
transcription, TFIIA has an important role in the regulation of
transcription. Together with a number of activators and coac-
tivators, TFIIA stimulates formation of the TFIID-TATA
complex, perhaps by forming a molecular bridge between the
regulatory proteins and TFIID (27, 33, 38, 61, 62, 71). Consis-
tent with this idea, TFIIA can interact directly with certain
activators (33, 51) and with a TAF (76). Moreover, crystallo-
graphic studies have shown that TFIIA binds to TBP and
contacts DNA upstream of the TATA box (16, 70). Finally, a
genetic screen of yeast identiﬁed a TBP mutant that is im-
paired in its response to acidic activators and defective for its
interaction with TFIIA (66).
In addition to its coactivator function, TFIIA can stimulate
transcription by counteracting the effects of certain repressors
that target TFIID (20). Some of these repressors, such as
Mot1/ADI, inhibit transcription by disrupting the TFIID-
TATA complex (4), while others, such as Dr1-DRAP1/NC2,
and HMG1, block subsequent steps in PIC assembly (14, 26,
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867345). TFIIA can also compete with TAFs that inhibit the DNA-
binding activity of TBP, providing a possible explanation for
the requirement of TFIIA in basal transcription reactions pro-
grammed with TFIID (34, 50). Interestingly, the coactivation
and antirepression activities of human TFIIA have been found
to reside in separable domains of the protein, conﬁrming that
TFIIA can employ both mechanisms to enhance TFIID func-
tion (40).
In S. cerevisiae, TFIIA is composed of two subunits, a 32-
kDa subunit encoded by the TOA1 gene and a 13.5-kDa sub-
unit encoded by the TOA2 gene (55). Both genes are essential
for cell viability and show striking similarity to the TFIIA-
encoding genes of higher eukaryotes. Several mutational stud-
ies have been performed to identify residues in TFIIA impor-
tant for its various functions. Deletion mutations in TOA1 and
TOA2 have identiﬁed regions of TFIIA required for subunit-
subunit interaction and for TBP and DNA binding (28). A
search for conditional mutations yielded temperature-sensitive
mutations in TOA1 that reduce formation of a TFIIA-TBP-
DNA complex and mutations in TOA2 that do not impair
TFIIA function in vitro (28). Site-directed mutagenesis of the
human small-subunit gene and the yeast TOA2 gene demon-
strated the importance of the TBP-TFIIA interaction for acti-
vation of speciﬁc genes in vitro and in vivo (48, 49).
Despite these genetic studies, our current understanding of
TFIIA derives mostly from its properties in highly puriﬁed,
reconstituted transcription systems. To begin to elucidate the
function and regulation of TFIIA in vivo, we have analyzed the
interaction of TFIIA with a class of TBP mutants that exhibits
promoter-speciﬁc defects in activated transcription in vivo (3).
One of the mutants in this class, TBP-N159D, which is encoded
by the spt15-341 mutation, has an amino acid substitution at a
position that directly contacts the TATA box. A second mutant
in this class TBP-P109A, which is encoded by the spt15-328
mutation, has a proline-to-alanine substitution within a loop
connecting two of the b strands that form the DNA-binding
surface of TBP (3, 29, 30). Both of these proteins are severely
compromised for DNA binding in vitro (1, 3). We have found
that TFIIA overexpression strongly suppresses the transcrip-
tional defects of the TBP mutants and that puriﬁed TFIIA
restores DNA binding to the one mutant that was tested. Using
a genetic screen, we have identiﬁed three regions of TFIIA
that are important for TBP recruitment or TBP-TATA com-
plex stabilization in vivo. Finally, using a method for condi-
tionally expressing TOA1, we have depleted Toa1 and demon-
strated that promoters vary signiﬁcantly in the degree to which
they require normal levels of TFIIA for activation. These re-
sults suggest that TFIIA coactivates transcription in a gene-
speciﬁc manner in vivo by facilitating or stabilizing the inter-
action of TBP with the TATA box.
MATERIALS AND METHODS
Yeast strains and media. Rich (YP), minimal (SD), synthetic complete (SC),
5-ﬂuoroorotic acid, and inositol starvation media were prepared as described
previously (58). YPGal and SCGal media contained 2% galactose. Solid YPGal
and SCGal media also contained 1 mg of antimycin A/liter. Yeast transformants
were selected on SC media lacking the appropriate nutrient.
With the exception of YJL1471 (a gift from C. S. Detweiler and J. J. Li), all
strains used in this study are congenic to FY2, a GAL2
1 ura3-52 derivative of
S288C (73). Strains were constructed by standard genetic procedures (58) and
are listed in Table 1. Strains containing the spt15 mutations were described
previously (3). Plasmids pKA92 and pKA100 are derivatives of pRS314 (63) that
contain the spt15-330 and spt15-338 mutations, respectively (3).
To introduce the toa1D100::LEU2 mutation into yeast, strain KY310 was
transformed with the 3.7-kb SalI-PstI fragment of pLQ14. Precise replacement of
one chromosomal copy of TOA1 was conﬁrmed by tetrad analysis and Southern
hybridization. To construct strains that were used in the Toa1 depletion exper-
iments, strain KY549 was transformed with plasmid pLQ36 prior to sporulation
and tetrad dissection. Segregants containing the toa1D100::LEU2 allele and
pLQ36 were subsequently transformed with the TOA1 fusion plasmids. To evict
pLQ36, Trp
1 transformants were transferred by replica plating to 5-ﬂuoroorotic
acid media lacking methionine.
Plasmids. Standard methods were used to construct plasmids, isolate DNA,
and transform DNA into Escherichia coli (5). All plasmids used in yeast trans-
formations were derived from the pRS series of shuttle vectors (10, 63). Plasmids
recovered by glass bead lysis of yeast (23) were transformed into E. coli MH1
(19) cells for ampliﬁcation.
Plasmids pLQ1, pLQ2, and pLQ3 used in the TFIIA overexpression experi-
ments were derived from plasmid pSH346, a gift from Steve Hahn. To generate
pLQ1, a 2.3-kb SalI-PstI fragment from pSH346 containing the wild-type TOA1
gene was inserted at the same sites in pRS425. The 2.0-kb PstI-PstI fragment
from pSH346, which contains the wild-type TOA2 gene, was inserted at the PstI
site of pRS425 or pLQ1 to give rise to pLQ2 or pLQ3, respectively. pLQ99 is a
2mm, URA3-marked plasmid that expresses both TOA1 and TOA2 and that was
constructed by inserting the 4.1-kb XhoI-BamHI fragment of pLQ3 into the same
sites of pRS426. pSB238, a gift from Steve Buratowski, is a pRS426 derivative
containing the SUA7 gene (53). For TOA1 mutagenesis, plasmid pLQ21 was
created by subcloning the 2.3-kb SalI-PstI fragment from pLQ1 into the same
sites of pRS314. For TOA2 mutagenesis, pLQ23 was generated by insertion of
the 2.0-kb PstI-PstI fragment from pLQ2 into the PstI site of pRS314.
Plasmids used for the in vitro transcription of TOA1 and TOA2 were con-
structed as follows. With pRS314 derivatives as templates, an MscI site was
introduced by PCR 5 bp 59 to the translation start codon of each TOA1 and
TOA2 gene (28). MscI-BamHI (from the polylinker) fragments containing wild-
type or mutant TOA1 genes were subcloned into the same sites of pCITE-4a (1)
(Novagen). For the TOA2 derivatives, a SalI site was also introduced by PCR
approximately 300 bp downstream of the translation stop codon. MscI-SalI frag-
ments containing wild-type or TOA2 genes were subcloned into the same sites of
pCITE-4a (1).
To generate a chromosomal deletion of TOA1, plasmid pLQ14 was con-
structed. First, the 2.3-kb SalI-PstI fragment from pLQ1 was inserted into the
same sites of pUC18, generating pLQ6. Second, pLQ6 was used as a template in
a PCR with divergent primers that annealed immediately adjacent to the ATG
and TAA codons of TOA1. The primers incorporated XhoI restriction sites into
the PCR product. Third, the 4.2-kb PCR product was cut with XhoI and self-
ligated to create plasmid pLQ7. Fourth, a 2.2-kb SacI-XbaI fragment containing
the LEU2 gene was excised from plasmid pGP43 (a gift from Greg Prelich),
blunted with a Klenow fragment, and inserted into the XhoI (blunted) site of
pLQ7 to create pLQ14.
The fusion genes used for Toa1 depletion experiments were derivatives of
plasmids bc64, bc65, bc66, and bc67 (11). These plasmids contain UBI-lacI-
SPT15 fusion genes under the control of the CUP1 promoter and differ in the
encoded amino acid at the junction between ubiquitin and LacI. The four
TABLE 1. S. cerevisiae strains
Strain Genotype
KY214..............................................................MATa spt15-328 his4-917d lys2-173R2 leu2D1 ura3-52 trp1D63
KY216..............................................................MATa spt15D102::LEU2 his4-917d lys2-173R2 leu2D1 ura3-52 trp1D63 [pKA92]
KY224..............................................................MATa spt15D102::LEU2 his4-917d lys2-173R2 leu2D1 ura3-52 trp1D63 [pKA100]
KY230..............................................................MATa spt15-336 his4-917d lys2-173R2 leu2D1 ura3-52 trp1D63
KY231..............................................................MATa spt15-341 his4-917d lys2-173R2 leu2D1 ura3-52 trp1D63
KY549..............................................................MATa/MATa toa1D::LEU2/TOA1 lys2-128d/lys2-128d leu2D1/leu2D1 ura3-52/ura3-52 trp1D63/trp1D63
KY550..............................................................MATa toa1D::LEU2 lys2-128d leu2D1 ura3-52 trp1D63 [pLQ55]
KY551..............................................................MATa toa1D::LEU2 lys2-128d leu2D1 ura3-52 trp1D63 [pLQ56]
KY552..............................................................MATa toa1D::LEU2 lys2-128d leu2D1 ura3-52 trp1D63 [pLQ57]
FY83................................................................MATa/MATa lys2-128d/lys2-128d leu2D1/leu2D1 ura3-52/ura3-52 trp1D63/trp1D63
FY630..............................................................MATa his4-917d lys2-173R2 leu2D1 ura3-52 trp1D63
YJL1471..........................................................MATa leu2-3,112 ura3-52 trp1-289 bar1::LEU2 [pMET-(HA)3-CDC6]
8674 LIU ET AL. MOL.C ELL.B IOL.plasmids were cut with BamHI to remove the CUP1 promoter and UBI gene and
religated to generate pLQ9, pLQ10, pLQ11, and pLQ12. TOA1 was ampliﬁed
from plasmid pLQ6 with primers that incorporated an XbaI site at the ATG and
a SalI site approximately 300 bp 39 of the stop codon. The TOA1 open reading
frame of the PCR product was sequenced with an ABI PRISM 377 sequencer.
The 1.2-kb PCR products were digested with XbaI and SalI and then inserted at
the same sites in pLQ9, pLQ10, pLQ11, and pLQ12 to replace the SPT15 gene.
The BamHI-BamHI fragment containing the CUP1 promoter and UBI gene was
inserted back into the newly made plasmids. Finally, to express TOA1 from the
MET3 promoter, EcoRI-SalI fragments containing UBI-lacI-TOA1 fusion genes
were excised from the CUP1 plasmids, made blunt by treatment with Klenow
fragment, and inserted at the blunted EcoRI site of pRN500. Plasmid pRN500 is
a derivative of pRS414 and contains the MET3 promoter (a gift from R. Nash).
The resulting plasmids, pLQ54, pLQ55, pLQ56, and pLQ57, contain arginine,
methionine, isoleucine, and tyrosine, respectively, at the junction between ubiq-
uitin and LacI.
Isolation of TFIIA mutants. The TOA1 and TOA2 genes were ampliﬁed from
plasmids pLQ21 and pLQ23 by error-prone PCR (78). Primers that annealed to
sequences on the pRS314 vector outside the polylinker were used. To generate
a toa1 library, ampliﬁed fragments were digested with SalI and PstI and inserted
into SalI-PstI-digested pRS314 (CEN ARS TRP1 vector). To generate a toa2
library, ampliﬁed fragments were cut with PstI and inserted into the PstI site of
pRS314. Strain KY214 was transformed with the toa1 and toa2 mutant libraries,
and transformants were replica plated to a series of media to test inositol
auxotrophy, galactose utilization, and temperature sensitivity. To determine if
the TOA1 mutations affected the four-helix bundle or b-sandwich region of the
protein, in vivo mapping experiments were performed (46). All TOA1 mutations
that were able to suppress the mutant TBP mapped to the b-sandwich coding
region. DNA sequencing of this region revealed the nature of the TOA1 muta-
tions. TOA2 mutations were identiﬁed by sequencing the entire TOA2 gene.
Saturation mutagenesis. An oligonucleotide was designed to incorporate ran-
dom changes at codon 254 of TOA1 and was used in a site-directed mutagenesis
reaction (43) with plasmid pLQ21 to construct a plasmid library of toa1 muta-
tions. Sequencing the DNA of 10 randomly chosen library clones showed that the
mutagenesis frequency was approximately 40%. This library was then trans-
formed into KY214 and screened for mutations that suppress the phenotypes
conferred by spt15-328. Of 900 transformants, plasmids from 15 candidates were
recovered, passaged through E. coli, and retransformed into KY214. Eleven
plasmids that retained suppression were sequenced in the region encompassing
codon 254 of TOA1.
RNA analysis. Cells were grown at 30°C to 1 3 10
7 to 2 3 10
7 cells/ml in the
appropriate media, and transcription of INO1, GAL1, GAL10, and CUP1 was
induced as described in the ﬁgure legends (see also reference 3). RNA isolation
and Northern hybridization analysis were performed by procedures described
previously (3). DNA probes were derived from plasmids pJH310 (INO1) (22),
pGAL1-GAL10 (EcoRI fragment 4812 [67] in pUC18), pCC69 (ACT1; a gift
from F. Winston), pKA110 (GAL4) (1), pFW45 (HIS4) (74), and pLD2 (CUP1;
a gift from M. Grunstein). Transcript levels were quantitated with a FUJIX
BAS2000 phosphorimager with MacBAS, version 2.4, software.
Depletion of TFIIA with the MET3 promoter. To analyze gene activation upon
TFIIA depletion, yeast strains YJL1471 expressing (HA)3-CDC6 and KY552
expressing UBI-lacI-TOA1 (Y), in which the fusion genes are both under the
control of the MET3 promoter, were grown at 30°C in the appropriate nonin-
ducing media lacking methionine to an optical density at 600 nm (OD600) of 0.3.
To repress transcription of (HA)3-CDC6 and UBI-lacI-TOA1 (Y), L-methionine
was added to a ﬁnal concentration of 1 mM. To maintain cells in log-phase
growth, the OD600 was measured every hour throughout the course of the
experiment and cultures were repeatedly diluted to an OD600 of 0.3 with the
appropriate media. The transcription of CDC6 and TOA1 was repressed by
exposure to methionine for the times indicated in the ﬁgure legends so that
similar percentages of cell survival were obtained. Subsequently, transcription of
INO1, GAL1, GAL10, HIS4, and CUP1 was induced by adding the appropriate
chemicals. Samples were taken for RNA preparation and Northern analysis.
Percent viability was determined by spreading duplicate samples of cells from the
depleted (with methionine) and nondepleted (without methionine) cultures on
SC medium lacking methionine. To measure levels of the ubiquitin-LacI-Toa1
fusion protein, whole-cell extracts were prepared essentially as described previ-
ously (68). Protein extract from 0.25 OD600 unit of cells was loaded in each lane
and analyzed by immunoblotting with rabbit polyclonal antisera directed against
Toa1. Fusion Toa1 protein levels were quantitated on a Power Macintosh
7100/80 computer with the public-domain National Institutes of Health Image
program and normalized to ribosomal protein L3 levels. During the course of our
experiments, we noticed that the kinetics of Toa1 depletion in SD and SC media
differed slightly. Therefore, to allow a meaningful comparison of the effects of
TFIIA depletion at different promoters, control experiments were performed to
establish the time needed to deplete Toa1 levels to less than 5% of undepleted
levels in both media conditions.
In vitro DNase I footprinting assays and electrophoretic mobility shift assays.
A radiolabelled DNA probe containing the adenovirus major-late TATA box was
prepared from plasmid pRW essentially as described previously (2). Wild-type
TBP and TBP-N159D were puriﬁed from E. coli overexpression strains by stan-
dard chromatographic procedures (7, 52). The wild-type TBP used in all exper-
iments was approximately 95% pure, and the TBP-N159D preparations used in
DNase I footprinting and electrophoretic mobility shift assays were approxi-
mately 45 and 95% pure, respectively. Recombinant yeast TFIIA, which was
approximately 70% pure, was a gift from Tony Imbalzano and Robert Kingston.
In DNase I footprinting assays, wild-type TBP and TBP-N159D were incubated
for 30 min at 30°C with ,1 ng of the pRW probe in a reaction volume of 25 ml.
Buffer conditions were as described previously (2). In the reaction mixtures that
contained recombinant yeast TFIIA, 670 nM TFIIA was added before the incu-
bation. This amount of TFIIA was found to be saturating for TFIIA-TBP-DNA
ternary complex formation with both wild-type TBP and TBP-N159D. Samples
were treated with DNase I and processed as described previously (2). In elec-
trophoretic mobility shift assays, 15 nM recombinant yeast TBP and 2 ml of 1:100
dilutions of in vitro-translated TFIIA were incubated with the pRW probe for 30
min at 30°C under previously described conditions (13). TOA1 and TOA2 genes
were transcribed in vitro with T7 RNA polymerase (Stratagene). Toa1 and Toa2
were cotranslated with a rabbit reticulocyte lysate system (Promega). [
35S]me-
thionine was added to a portion of each translation reaction mixture to compare
amounts of protein made. Sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis analysis of these parallel reactions demonstrated that the electro-
phoretic mobility shift assay mixtures contained equivalent amounts of TFIIA
(39). Electrophoretic mobility shift assays, carried out with unlabeled translation
products, were analyzed on nondenaturing 4% polyacrylamide gels at room
temperature (13).
RESULTS
Overexpression of TFIIA suppresses phenotypes caused by
activation-defective TBP mutants. To investigate the impor-
tance of TFIIA in the recruitment of TBP to TATA elements
in vivo, we have tested the ability of TFIIA to restore function
to a class of TBP mutants that is activation and DNA binding
defective (3). In our initial experiments, we asked whether
overexpression of TFIIA could suppress the characteristic phe-
notypes, inositol auxotrophy (Ino
2) and slow growth on galac-
tose-containing media (Gal
2), of ﬁve different TBP mutant
strains in this class. High-copy-number plasmids expressing
both TOA1 and TOA2 were transformed into the strains, and
suppression was examined by replica plating the transformants
to selective media lacking inositol or containing galactose. In
addition, for experiments involving the temperature-sensitive
(Ts
2) spt15-328 mutation, transformants were analyzed for
their ability to grow at 37°C. As shown in Fig. 1A and Table 2,
the Ino
2, Gal
2, and Ts
2 phenotypes of the TBP mutant strains
were signiﬁcantly suppressed when both TOA1 and TOA2 were
present on the 2mm plasmid. Speciﬁcity of suppression is in-
dicated by the inability of TOA1 or TOA2 alone to reverse the
mutant phenotypes (Fig. 1A) (39). Overexpression of TFIIA in
these strains was conﬁrmed by immunoblot analysis (39).
Previously, TFIIA and TFIIB have been shown to increase
the afﬁnity of wild-type TBP for the TATA box under subop-
timal binding conditions (25). To test if TFIIB can also sup-
press the phenotypes caused by the mutant TBPs, SUA7, the
gene that encodes TFIIB in S. cerevisiae, was overexpressed in
spt15-328 and spt15-341 mutant strains. Unlike the strong sup-
pression observed upon TFIIA overexpression, the high-copy-
number SUA7 plasmid did not suppress the Ino
2, Gal
2,o rT s
2
phenotypes caused by TBP-P109A and TBP-N159D (Fig. 1B)
(39). The presence of high levels of TFIIB in these strains was
conﬁrmed by immunoblot analysis (39). Together, these ﬁnd-
ings indicate that suppression of the activation- and DNA
binding-defective TBP mutants is speciﬁc to TFIIA overex-
pression and suggest that TFIIA and TFIIB differ in their
abilities to enhance the TBP-TATA interaction in vivo.
Overexpression of TFIIA restores transcriptional activation
in the TBP mutant strains. The inositol auxotrophy and ga-
lactose utilization defect caused by TBP-P109A and TBP-
N159D correlate strongly with reduced transcriptional activa-
tion of the INO1, GAL1, and GAL10 genes (3). To determine
whether TFIIA overexpression can rescue these activation de-
fects in the TBP mutant strains, Northern analyses were per-
VOL. 19, 1999 PROMOTER-SPECIFIC ROLE FOR TFIIA IN TBP FUNCTION 8675formed. In wild-type strains, transcription of the INO1 gene is
repressed by high levels of inositol and is dramatically induced
when levels of inositol are low (Fig. 2A, lanes 3 and 4). How-
ever, in agreement with previous results (3), transcriptional
activation of INO1 is severely impaired in strains that contain
TBP-P109A or TBP-N159D (Fig. 2A, lanes 8 and 12). Whereas
overexpression of TFIIA does not affect transcriptional activa-
tion of INO1 in strains containing wild-type TBP (Fig. 2A,
lanes 1 and 2), overexpression of TFIIA in the TBP mutant
strains restores activated transcription of INO1 to approxi-
mately 40 and 30% of wild-type levels for TBP-P109A and
TBP-N159D, respectively (Fig. 2A, lanes 6 and 10). A similar
result for the galactose-induced GAL1 and GAL10 genes was
observed. For GAL1, overexpression of TFIIA in strains that
contain TBP-P109A and TBP-N159D raises the activated-tran-
scription levels to approximately 30 and 15%, respectively, of
the levels observed in strains that contain wild-type TBP (Fig.
2B, lanes 6 and 10). These results reveal that suppression of
the Ino
2 and Gal
2 phenotypes of the TBP mutant strains
occurs at the transcriptional level. In addition, they demon-
strate that the requirement for a transcriptional activator can-
not be bypassed by an increase in TFIIA levels, as TFIIA
overexpression does not lead to constitutive expression of
INO1, GAL1,o rGAL10. Instead, TFIIA apparently functions
as a coactivator at these promoters.
TFIIA restores DNA binding to TBP-N159D in vitro. TBP-
P109A and TBP-N159D are severely defective for binding to
TATA elements in vitro, yet yeast strains that contain these
mutant TBPs as the only source of TBP activity are viable (3).
FIG. 1. TFIIA overexpression suppresses the phenotypes conferred by TBP-P109A. (A) Yeast 2mm plasmids carrying TOA1, TOA2, or both genes were transformed
into strain KY214. Transformants were replica plated to selective media to assay inositol auxotrophy, galactose utilization, or temperature sensitivity (SC). For the Ino
and Ts phenotypes, plates were incubated at 30°C for 3 days. For the Gal phenotype, plates were incubated at 30°C for 4 days. (B) A yeast 2mm plasmid carrying SUA7
and a vector control were transformed into KY214 and replica plated to the indicated media. Plates were incubated at 30°C for 4 days to monitor the Ino andT s
phenotypes or for 5 days for the Gal phenotype.
TABLE 2. Suppression of TBP mutants by TFIIA overexpression
a
Amino acid
change Allele
Suppression of phenotype
Ino Gal Ts
TBP-P109A spt15-328 1/21 /22 1
TBP-N159D spt15-341 2/12 2 /1 NA
TBP-V71A spt15-330 1/22 2/1 NA
TBP-F116Y spt15-336 1/22 2/1 NA
TBP-V161A spt15-338 1/22 22/1 NA
a Strains containing the indicated spt15 mutations were transformed with 2mm
plasmids (pLQ3 or pLQ99) expressing both TOA1 and TOA2. The Ino and Ts
phenotypes were scored after 3 days of growth at 30°C, and the Gal phenotype
was scored after 5 days. Very strong, strong, moderately strong, moderate, weak,
and no suppression are indicated by the symbols 1, 1/2, 1/22, 2/1, 22/1,
and 2, respectively. With the exception of TBP-V71A, which has not been
tested, each of the TBP mutants has been shown to be DNA binding defective (3,
37, 57). A related mutant, TBP-V71E, also has greatly reduced afﬁnity for DNA
(57). NA, not applicable.
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the extreme DNA-binding defects of these mutants. To de-
termine whether TFIIA can restore TATA box binding to the
mutant TBPs, we puriﬁed recombinant TBP-N159D and test-
ed its ability to bind to the adenovirus major-late promoter
(AdMLP) TATA box in the presence and absence of recom-
binant yeast TFIIA. In agreement with previous results from
electrophoretic mobility shift assays (3), DNase I footprinting
clearly demonstrates that, relative to wild-type TBP, TBP-
N159D has greatly reduced afﬁnity for the AdMLP TATA box.
We detected no protection of the TATA box, even when the
amount of TBP-N159D in the reaction mixture was 40-fold
greater than the amount of wild-type TBP needed for half-
maximal binding (Fig. 3A). However, in the presence of satu-
rating amounts of yeast TFIIA, TBP-N159D protects the
TATA region to levels similar to those observed with equiva-
lent molar amounts of wild-type TBP (Fig. 3B). These results
are in good agreement with an earlier study, which investigated
the effects of TFIIA on a different set of TBP DNA-binding
mutants (36). In conjunction with our genetic results on TFIIA
overexpression, these ﬁndings demonstrate that TFIIA can
overcome substantial impediments to TBP-TATA complex
formation and support models in which TFIIA plays a role in
TBP recruitment in vivo.
Suppression of mutant TBPs by dominant mutations in
TOA1 and TOA2. The strong mutant phenotypes caused by
TBP-P109A and TBP-N159D allowed us to perform a genetic
screen for mutations in TOA1 and TOA2 that suppress these
mutant TBPs and, therefore, might facilitate the TBP-TATA
interaction in vivo. TOA1 and TOA2 were mutagenized by
PCR, and ampliﬁed fragments were used to construct mutant
toa1 and toa2 libraries. The libraries were transformed into a
strain containing TBP-P109A, and transformants were screened
for suppression of the Ino
2, Gal
2, and Ts
2 phenotypes. Since
the endogenous wild-type copies of TOA1 and TOA2 were
present in the strain, the suppressor mutations were expected
to be dominant.
For the analysis of TOA1, a screen of 24,000 transformants
yielded 29 candidates that carried plasmid-borne mutations
responsible for suppression of TBP-P109A. Nineteen showed
suppression of both the Ino
2 and Ts
2 phenotypes, while 10
exhibited suppression of only the Ino
2 phenotype. Since we
have demonstrated that overexpression of TFIIA can reverse
the mutant phenotypes conferred by TBP-P109A, TFIIA levels
in these 29 candidates were assayed by immunoblotting. None
of the 29 candidates exhibited TFIIA levels different from
those of the wild type (39). An in vivo mapping strategy (46)
was used to show that all of the TOA1 mutations affect the
b-sandwich region of Toa1 (39). DNA sequencing revealed
that among the 10 Ino
1 candidates 6 encode the change S261R
and four encode Q280R. Eleven Ino
1 Ts
1 candidates encode
the change D226V, seven encode T254I, and one encodes
T254K. On the TFIIA-TBP-DNA crystal structures, Thr254
and Ser261 lie within a region of Toa1 that contacts DNA (16,
70) (Fig. 4A). Gln280 occupies a position near Ser261, but on
the adjacent b-strand, and may also be involved in contacting
the promoter upstream of the TATA box (Fig. 4A). In con-
trast, Asp226 lies in a very acidic, solvent-exposed region of
Toa1 that exhibits no direct contacts with TBP or DNA and,
therefore, represents a possible site for regulatory interactions
(15, 16). The degree of suppression caused by these amino acid
changes in Toa1 is summarized in Table 3.
Because we recovered two different substitutions for Thr254
in our screen, we investigated the speciﬁcity of these changes
by performing saturation mutagenesis. Codon 254 was ran-
domized by site-directed mutagenesis. A plasmid library con-
structed from the mutagenesis products was transformed into
a strain containing TBP-P109A. Of 900 transformants screened,
11 contained plasmid-encoded TOA1 mutations that were able
to suppress the Ino
2 and/or Ts
2 phenotypes of the strain.
Among the six strong Ino
1 Ts
1 TOA1 suppressors, ﬁve encode
the T254K substitution and one encodes the T254I change.
Among the ﬁve weak Ino
1 suppressors, four change Thr254 to
arginine and one encodes a glutamine at this position. These
results indicate that only speciﬁc substitutions at residue 254 of
Toa1, and not simple loss of a potential site of phosphoryla-
tion, suppress the activation- and DNA binding-defective TBP
mutant.
To identify amino acids in Toa2 that are potentially impor-
tant for recruitment of TBP to TATA elements in vivo,
we constructed two independent toa2 mutant libraries and
screened 26,000 transformants for suppression of TBP-P109A.
After puriﬁcation and retransformation, 11 candidates con-
tained plasmid-encoded TOA2 mutations that partially re-
versed the Ino
2 phenotype conferred by TBP-P109A. The 11
mutant TOA2 genes were sequenced in their entirety. Five
mutations change Gly30 to arginine, and four encode a glu-
tamic acid at this position. Gly30 lies at the tip of the solvent-
exposed four-helix bundle domain of TFIIA (16, 70) (Fig. 4A).
The remaining two mutations encode the substitution E88K.
As shown on the TFIIA-TBP-DNA crystal structure (Fig. 4A),
Glu88 of Toa2 lies on the surface of TFIIA that contacts DNA,
and the introduction of a lysine at this position may extend the
TFIIA-DNA interaction upstream of the TATA box. Suppres-
sion of TBP-P109A by each of these TOA2 mutations is highly
reproducible but noticeably weaker than suppression by the
TOA1 mutations we identiﬁed (Table 3).
Plasmids expressing the dominantly acting TOA1 and TOA2
mutations were also transformed into a strain containing TBP-
FIG. 2. TFIIA overexpression suppresses the INO1, GAL1, and GAL10 tran-
scriptional defects caused by TBP-P109A and TBP-N159D. (A) Northern anal-
ysis of INO1 transcription in strains that overexpress TFIIA. Yeast strains con-
taining wild-type TBP (KY300), TBP-P109A (KY214), or TBP-N159D (KY231)
were transformed with plasmid pLQ3 (2mm, TOA1 and TOA2) or pRS425
(vector control) and grown in repressing (R; 200 mM inositol) and derepressing
(D; 10 mM inositol) conditions. (B) Northern analysis of GAL1 and GAL10
transcription in strains that overexpress TFIIA. The same yeast strains used in
panel A were grown in noninducing (N; 2% rafﬁnose) and inducing (I; 2%
rafﬁnose plus 5% galactose) conditions. In each case, the ﬁlter used in the upper
panel was stripped and probed for ACT1 message as a normalization control.
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pression by the TOA1 and TOA2 mutations paralleled the
results observed with TBP-P109A (Table 3). TOA1 mutations
that altered residues on the TFIIA-DNA interface strongly
suppressed the Ino
2 phenotype conferred by TBP-N159D,
while the TOA2 mutations resulted in signiﬁcantly weaker
levels of suppression. Interestingly, the Toa1-D226V mu-
tant, which strongly suppressed TBP-P109A, failed to sup-
press TBP-N159D. Indeed, this Toa1 mutant appeared to
exert a dominant-negative effect on TBP-N159D, causing a
stronger Ino
2 phenotype than that conferred by TBP-N159D
alone. The basis for the differential behavior of Toa1-D226V in
strains containing TBP-P109A and TBP-N159D is considered
in the Discussion. All of the TOA1 and TOA2 mutations that
were tested (i.e., all except Toa1-Q280R and Toa2-E88K) are
sufﬁcient to support viability in strains containing wild-type TBP
and a disruption of the appropriate chromosomal TOA gene
(39).
One explanation for the suppressive effects of the dominant
TOA1 and TOA2 mutations, particularly those that introduce
basic residues on the TFIIA-DNA interface, is that they sta-
bilize or enhance formation of the TFIIA-TBP-DNA complex.
To test this possibility, electrophoretic mobility shift assays
were performed with in vitro-translated TFIIA, recombinant
yeast TBP, and the AdMLP TATA probe. TFIIA mutant pro-
teins were synthesized by cotranslating a mutant subunit (e.g.,
Toa1-D226V) with its wild-type counterpart (e.g., wild-type
Toa2). Limiting, but equivalent (see Materials and Methods)
(39), amounts of wild-type and mutant TFIIA proteins were
added to the reaction mixtures so that any increase in complex
formation could be detected. Toa1 mutants with changes at
Thr254 and Ser261 exhibited increased formation or stability
of TFIIA-TBP-DNA complexes containing wild-type TBP (Fig.
4B, lanes 6 to 8). Relative to wild-type TFIIA, these mutants
gave rise to more discrete ternary complex bands and de-
creased dissociation in the native gel. In contrast, the Toa1-
D226V, Toa2-G30R, and Toa2-G30E mutants supported
TFIIA-TBP-DNA complex formation to approximately the
same degree as wild-type TFIIA (Fig. 4B; compare lane 4 with
lanes 5, 9, and 10). These results suggest that suppression by
the TFIIA mutants with amino acid substitutions on the DNA-
binding surface involves a direct effect on the assembly or
stability of the TFIIA-TBP-DNA complex. To further test this
hypothesis, similar assays were performed with recombinant
TBP-N159D. With the limiting amounts of in vitro-translated
TFIIA used in this experiment, wild-type TFIIA did not form
detectable levels of a stable TFIIA-TBP-DNA complex (Fig.
4C, lane 3). In contrast, an equivalent amount of the Toa1-
T254K mutant gave rise to a readily observable ternary com-
plex (Fig. 4C, lane 5). The Toa1-T254I and Toa1-S261R de-
rivatives supported only very low levels of complex formation
in this assay (Fig. 4C, lanes 6 and 7), while the remaining
mutants behaved similarly to wild-type TFIIA. Any signiﬁcant
differences among the latter mutants are masked by the overall
instability of the TBP-N159D-containing complexes in the elec-
trophoretic mobility shift assay. Nonetheless, the combined
results of these experiments, together with the nature and
locations of the amino acid changes, suggest that the dominant
TOA1 and TOA2 mutations suppress the TBP defects by dif-
ferent mechanisms, one of which involves a direct effect on the
assembly or stability of the TFIIA-TBP-DNA complex.
The requirement for TFIIA in transcriptional activation is
promoter speciﬁc. TBP-P109A and TBP-N159D exhibit pro-
moter-speciﬁc defects in transcriptional activation (3). Acti-
vated transcription of certain genes, such as INO1, GAL1, and
GAL10, is dramatically reduced in strains containing these
FIG. 3. TFIIA increases the afﬁnity of TBP-N159D for DNA in vitro. (A) DNase I footprinting assay of wild-type TBP and TBP-N159D binding to the AdMLP
TATA box. Reaction mixtures for lanes 5 to 10 contained wild-type TBP, and reaction mixtures for lanes 11 to 16 contained TBP-N159D. Amounts were as follows:
lanes 5 and 11, 7 nM; lanes 6 and 12, 15 nM; lanes 7 and 13, 30 nM; lanes 8 and 14, 60 nM; lanes 9 and 15, 120 nM; lanes 10 and 16, 240 nM. (B) DNase I footprinting
assay of wild-type TBP and TBP-N159D binding to the AdMLP TATA box in the presence of TFIIA. Recombinant yeast TFIIA (670 nM) was added to the reaction
mixtures in lanes 5 and 7 to 19. Reaction mixtures for lanes 6 to 12 contained wild-type TBP, and reaction mixtures for lanes 14 to 19 contained TBP-N159D. Amounts
were as follows: lanes 7 and 14, 7 nM; lanes 8 and 15, 15 nM; lanes 9 and 16, 30 nM; lanes 10 and 17, 60 nM; lanes 6, 11, and 18, 120 nM; lanes 12 and 19, 240 nM.
Lanes 1 to 3 in each panel contain the products of DNA sequencing reactions. In these assays, we did not detect a signiﬁcant TFIIA-dependent increase in the afﬁnity
of wild-type TBP for DNA, presumably because conditions optimal for TBP-TATA complex formation were used (25).
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and HIS4, is largely unaffected. These results suggest that tran-
scriptional control at certain promoters is very sensitive to the
stability of the TBP-TATA complex. Since TFIIA increases the
afﬁnity of TBP for DNA in vitro (25, 36, 72, 77) (see above)
and since TFIIA overexpression restores activation to strains
containing TBP-P109A or TBP-N159D, we reasoned that pro-
moters may differ in the degree to which they require TFIIA
for regulated transcription. Speciﬁcally, the properties of the
TBP mutant strains suggested that activation of INO1, GAL1,
and GAL10 may be more dependent upon the activity of
TFIIA than activation of other promoters, such as HIS4.T o
test this hypothesis, we analyzed transcriptional activation
from several highly regulated promoters in strains that contain
wild-type TBP and reduced levels of TFIIA.
To conditionally deplete TFIIA in vivo, four different fusion
genes that encode unstable versions of Toa1 were placed under
the control of the methionine-repressible MET3 promoter
(Fig. 5A). A related strategy was employed by Cormack and
Struhl (11) for the depletion of TBP in yeast. The stabilities of
the ubiquitin-LacI-Toa1 fusion proteins are governed by the
junctional amino acid between ubiquitin and LacI (6). The
predicted order of fusion protein stability is Met . Ile . Tyr .
Arg. The four fusion genes were each introduced into a hap-
loid strain in which the endogenous TOA1 gene was disrupted.
Toa1 fusion proteins with Met, Ile, or Tyr at the junction
between ubiquitin and LacI can support life in media lacking
methionine (Fig. 5B), while a strain containing the Arg deriv-
ative as the only source of Toa1 was inviable under all condi-
tions tested. Importantly, cells expressing the Met, Ile, or Tyr
derivatives were inviable on media that contained methionine
(Fig. 5B). In liquid cultures, the Tyr derivative exhibited the
slowest growth rate upon transfer to media containing methi-
onine (39). Therefore, a strain containing this fusion was cho-
sen to perform the depletion experiments described below and
will be referred to as the Toa1 depletion strain.
To investigate the requirement for TFIIA in the activation
of various genes, we used the following strategy. First, the Toa1
depletion strain was grown to early log phase in media that
lacked methionine and that was noninducing for the gene of
FIG. 4. Effects of TOA1 and TOA2 mutations on TBP-TFIIA-DNA complex
formation. (A) Locations of the amino acids altered by the dominant TOA1 and
TOA2 mutations on the TFIIA-TBP-DNA crystal structure. Affected amino
acids are highlighted in yellow for Toa1 and in red for Toa2. TBP, DNA, Toa1,
and Toa2 are shown in blue, magenta, green, and white, respectively. The ﬁgure
was adapted from reference 70. The position of Asp226 could not be accurately
determined on this structure (70) and therefore is not indicated here. (B) Elec-
trophoretic mobility shift assays were performed with recombinant wild-type
TBP where indicated and a radiolabelled DNA probe containing the AdMLP
TATA box. Prior to incubating the reaction mixture at 30°C for 30 min, recom-
binant yeast TFIIA (40 nM; lane 3) or in vitro-translated TFIIA (lanes 4 to 10)
was added. Reaction mixtures for lanes 5 to 8 contained the indicated Toa1
mutant subunits cotranslated with wild-type Toa2, and reaction mixtures for
lanes 9 and 10 contained the indicated Toa2 mutant subunits cotranslated with
wild-type Toa1. Equivalent, but limiting, amounts of wild-type and mutant TFIIA
were added to the reaction mixtures (see Materials and Methods). Lanes 11 and
12 contained an unprogrammed translation reaction mixture. (C) Electro-
phoretic mobility shift assays were performed with recombinant TBP-N159D and
in vitro-translated TFIIA as described for panel B. A control reaction mixture
containing TBP-N159D and recombinant TFIIA was loaded on the same gel to
indicate the mobility of the TFIIA-TBP-DNA complex. The migration of this
complex is indicated by an arrow.
TABLE 3. Suppression of TBP mutants by dominant
TOA1 and TOA2 mutations
a
Protein
Suppression of indicated phenotype
in strains containing:
TBP-P109A TBP-N159D,
Ino Ino Ts
Wild-type Toa1 22 2
Toa1-D226V 1/21 2 2
Toa1-T254K 11 1
Toa1-T254I 11 1
Toa1-S261R 2/12 2 /1
Toa1-Q280R 1/22 1 /2
Wild-type Toa2 22 2
Toa2-G30R 22/12 2 2 /1
Toa2-G30E 22/12 2 2 /1
Toa2-E88K 22/12 ND
a Strains containing spt15-328 (TBP-P109A) or spt15-341 (TBP-N159D), en-
dogenous wild-type copies of TOA1 and TOA2, and the indicated TOA1 or TOA2
mutations were monitored for growth on media lacking inositol at 30°C. For
spt15-328, growth of strains was also monitored at 37°C on SC media lacking
tryptophan. Very strong, strong, moderate, weak, and no suppression after 3 days
of incubation are indicated by 1, 1/2, 2/1, 22/1, and 2, respectively. 22,
stronger Ino
2 phenotype caused by Toa1-D226V relative to wild-type Toa1 in
the spt15-341 background. ND, not determined.
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to deplete Toa1, and after a period of incubation, cells were
transferred to conditions that were activating for gene expres-
sion. For each medium condition, control experiments were
performed to determine the optimal amount of time needed
for Toa1 depletion, which was measured by immunoblot anal-
ysis and cell viability (Fig. 5C).
Our results show that INO1 activation is extremely sensitive
to TFIIA levels (Fig. 6A). Following3ho fexposure to me-
thionine, a time sufﬁcient to reduce Toa1 levels to approxi-
mately 5% of the nondepleted levels (Fig. 5C), cells were
washed and transferred to media that lacked inositol but still
contained methionine. Activation of INO1 transcription fol-
lowing the depletion period was signiﬁcantly impaired. At the
time of maximal INO1 induction, the culture that was depleted
of Toa1 produced only 12% of the activated INO1 transcript
levels that were observed in the absence of Toa1 depletion
(Fig. 6A; compare lanes 17 and 23). To control for the effect of
cell death in this and subsequent experiments, we analyzed
transcriptional activation in a strain depleted of an essential
protein, Cdc6, that is unrelated to RNA polymerase II tran-
scription. In this control strain, transcription of CDC6, which
encodes a protein required for DNA replication in yeast (21),
is also directed by the MET3 promoter. Even when Cdc6 levels
FIG. 5. Depletion of TFIIA with the MET3 promoter. (A) Fusion genes comprised of UBI, lacI, and TOA1 are under the control of the MET3 promoter. The amino
acid at the junction of ubiquitin and LacI is either M, I, Y, or R. (B) Three strains expressing, as their only source of Toa1, ubiquitin-LacI-Toa1 fusion proteins with
the indicated junctional amino acids were streaked on plates lacking (2MET) or containing methionine (1MET) and were grown at 30°C for 3 days. A strain containing
a wild-type (Wt) TOA1 gene is included for comparison. (C) Correlation between levels of the ubiquitin-LacI-Toa1 fusion protein and cell viability. KY552 expressing
ubiquitin-LacI-Toa1(Y) was grown to early log phase in SC (triangles) or SD (squares) media lacking methionine. Methionine was added at zero time to repress
transcription of the fusion gene. Samples were taken at the indicated times and assayed for cell viability (solid symbols) and fusion protein levels (open symbols). Fusion
protein levels were quantitated from immunoblots. At each of the time points, an immunoreactive band with a mobility similar to that of recombinant Toa1 was observed
(not shown). The levels of this protein did not change substantially over the time course. Conﬁrmation that this protein represents a Toa1 derivative was not made.
However, the reduction in cell viability detected upon methionine addition indicates that this protein cannot substitute for wild-type Toa1.
8680 LIU ET AL. MOL.C ELL.B IOL.were reduced so that cell viability was less than that of the
Toa1-depleted culture, INO1 activation was largely unaffected
(Fig. 6A; compare lanes 5 and 11). Therefore, the striking
decrease in INO1 activation observed in the Toa1-depleted
strain is not due to an indirect effect of cell death caused by the
loss of an essential protein. These ﬁndings suggest that TFIIA
plays a critical role in INO1 activation even in the presence of
a fully functional TBP.
We next analyzed the effect of TFIIA depletion on two other
genes, GAL1 and GAL10, whose transcription is affected by
the activation-defective TBP mutants. For these experiments,
the Toa1 and Cdc6 depletion strains were ﬁrst grown in raf-
FIG. 6. TFIIA depletion impairs activation at INO1, GAL1, and GAL10. Northern analyses of INO1 (A) and GAL1-GAL10 (B) transcription following depletion
of TFIIA are shown. Cdc6 and Toa1 depletion strains were grown to early log phase in media that lacked methionine and that was repressing (200 mM inositol for INO1)
or noninducing (2% rafﬁnose for GAL genes) for the gene of interest. Transcription of CDC6 and TOA1 was inhibited by the addition of 1 mM methionine where
indicated, and the incubation was continued for times sufﬁcient to achieve approximately equal levels of cell viability, as determined from control experiments.
Subsequently, strains were transferred to derepressing media (lacking inositol for INO1 and 5% galactose for GAL1-GAL10). Times of exposure to methionine prior
to gene activation were as follows for the Cdc6 and Toa1 depletion strains, respectively: 2 and3hf o rINO1 and 2 and 6 h for GAL1-GAL10. (C) Effect of GAL4
overexpression on GAL1-GAL10 induction. Strains carrying a GAL4 overexpression plasmid or control vector were grown as described for panel B except that the
cultures were treated with methionine for 8 h prior to the addition of 5% galactose. Samples were taken for Northern analysis at the indicated times after gene induction.
The zero-hour sample was removed prior to exposing cells to inducing conditions. RNA levels were normalized by measuring the A260 and by ethidium bromide staining
of control gels to visualize rRNA.
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half of each culture for times sufﬁcient to achieve comparable
levels of cell death. For the Toa1 depletion strain, this treat-
ment lowered Toa1 protein levels to less than 5% of nonde-
pleted levels (Fig. 5C). GAL1 and GAL10 transcription was
then induced by the addition of galactose. As shown in Fig. 6B,
activation of these Gal4-regulated genes was signiﬁcantly
impaired under conditions of Toa1 depletion. The levels of
GAL1 and GAL10 transcripts produced by the Toa1 deple-
tion strain in the presence of methionine were 6 and 5%,
respectively, of those produced in the absence of methionine
at the time of maximal induction for the nondepleted strain
(Fig. 6B; compare lanes 15 and 21). A reduction in GAL
gene transcription was not observed upon depletion of
Cdc6, indicating that the effect was not due to a loss in cell
viability.
Activation of GAL1 and GAL10 is extremely sensitive to the
amount of Gal4 in the cell (18). Therefore, the reduction in
GAL gene activation observed upon Toa1 depletion could
simply be a consequence of reduced activator levels. Indeed,
Toa1 depletion resulted in a fourfold decrease in GAL4 mes-
sage levels (Fig. 6B, middle; compare lanes 13 to 18 and lanes
19 to 24). To determine whether the impaired activation of
GAL1 and GAL10 was due entirely to lowered Gal4 levels, we
tested the effect of Toa1 depletion in strains that overex-
pressed Gal4 from a 2mm plasmid. In these strains, Toa1 de-
pletion reduced GAL4 transcript levels as expected; however,
the amount of GAL4 mRNA following depletion was still ap-
proximately twofold greater than that observed in a control
strain that carried empty vector and that was not depleted of
Toa1 (Fig. 6C; compare lanes 7 to 12 with lanes 13 to 18).
When the Gal4-overexpressing strain was exposed to methio-
nine to deplete Toa1 and then treated with galactose, tran-
scription of GAL1 and GAL10 was still impaired (Fig. 6C;
compare lanes 7 to 12 with lanes 13 to 18). These results
suggest that lowered activator levels are not solely responsible
for the GAL1-GAL10 activation defect and support a direct
role for TFIIA in Gal4-mediated activation.
To determine the importance of TFIIA in Gcn4-mediated
activation, we analyzed transcription of HIS4 under conditions
of Toa1 depletion. To induce Gcn4 synthesis, 3-aminotriazole
was added following the depletion of Toa1 (less than 5% of
nondepleted levels; Fig. 5C). HIS4 stimulation with and with-
out Toa1 depletion was by 2.3-fold and 2.4-fold, respectively
(Fig. 7A, lanes 11 and 14 and lanes 16 and 19). These results
suggest that activation of HIS4 is less sensitive than INO1,
GAL1, and GAL10 to the levels of TFIIA in the cell. The
mechanism that accounts for the decreased sensitivity of HIS4
to the TBP mutants may also lessen the dependence of this
promoter on TFIIA.
Relative to INO1 and the GAL genes, HIS4 is only moder-
ately induced by its activator, Gcn4. To ﬁnd out whether these
promoters differ in their requirement for TFIIA because they
differ in their level of induction, we tested another highly
activated promoter, CUP1, for its response to the TBP mutants
and Toa1 depletion. Strikingly, activation of CUP1 by copper
was unaffected by the TBP mutants, TBP-P109A and TBP-
N159D (Fig. 7B). In addition, a reduction in Toa1 levels to less
than 5% of nondepleted levels had no effect on the magnitude
of CUP1 induction: with and without depletion of Toa1, the
activation of CUP1 was by 17-fold and 13-fold, respectively
(Fig. 7C, lanes 11 and 13 and lanes 16 and 18). These results
demonstrate that at least one highly induced promoter is
largely insensitive to the stability of the TBP-TATA complex
or to TFIIA levels. These ﬁndings strongly suggest that the
requirement for TFIIA in transcriptional activation varies at
different promoters.
DISCUSSION
One important mechanism by which transcriptional activa-
tors stimulate gene expression is by accelerating the rate-lim-
iting binding of TBP to the TATA box. Biochemical experi-
ments have demonstrated a requirement for TFIIA and TAFs
in communicating the activation signal to TBP. In this study,
we sought to elucidate the role of TFIIA in transcriptional
activation in vivo by exploiting the properties of a well-char-
acterized class of TBP mutants (3). Three signiﬁcant ﬁndings
concerning the in vivo function of TFIIA have come from this
FIG. 7. TFIIA depletion does not impair activation of HIS4 or CUP1. (A)
Northern analysis of HIS4 transcription following depletion of TFIIA. Cdc6 and
Toa1 depletion strains were grown to early log phase in media that lacked
methionine. Where indicated, transcription of CDC6 and TOA1 was inhibited by
exposure of the cells to 1 mM methionine for 2.5 and 4 h, respectively. To induce
HIS4 transcription, 10 mM 3-aminotriazole was added to each culture. Samples
were taken at the indicated times prior to (zero-hour point) or following induc-
tion. (B) Northern analysis of CUP1 transcription in strains containing wild-type
TBP (FY630) or the TBP mutants, TBP-P109A (KY214) and TBP-N159D
(KY231). For induction, cells were treated with 100 mM CuSO4 for 30 min prior
to harvesting. The ﬁlter shown in the upper panel was stripped and probed for
ACT1 mRNA as a normalization control. (C) Northern analysis of CUP1 tran-
scription following depletion of TFIIA. The experiment was conducted as de-
scribed for panel A, except that cells were exposed to methionine for 2.5 and 6 h
to achieve comparable levels of cell death for the Cdc6 and Toa1 depletion
strains, respectively. CuSO4 (100 mM) was added to activate CUP1. For panels A
and C, RNA levels were normalized by measuring the A260 and by ethidium
bromide staining of control gels to visualize rRNA. In panel C, the two rRNA
control gels were run for different periods of time.
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overexpressed or altered by mutation, can restore function to
the DNA binding- and activation-defective TBP mutants.
These results strongly suggest that TFIIA facilitates the TBP-
TATA interaction in vivo. Second, we have identiﬁed through
a genetic screen three distinct regions on TFIIA that affect
TBP recruitment or the stability of the TBP-TATA complex.
Third, using a conditional expression system, we have demon-
strated a promoter-speciﬁc involvement of TFIIA in transcrip-
tional activation.
Together with the ability of TFIIA to restore DNA binding
to TBP-N159D in vitro, our TFIIA overexpression results sug-
gest that TFIIA assists in the recruitment of TBP to promoters
in vivo. Although our data do not rule out an effect of TFIIA
on TBP-TATA complex dissociation, a recruitment role for
TFIIA is most consistent with previous biochemical studies
that employed puriﬁed factors or yeast extracts (38, 56, 71).
Our observation that overexpression of TFIIA causes an ob-
servable phenotype (i.e., suppression of the activation-defec-
tive TBP mutants) suggests that TFIIA may be limiting in vivo,
at least at certain promoters. Interestingly, TFIIA overexpres-
sion also reverses the mutant phenotypes conferred by an un-
related TBP mutant, encoded by the spt15-21 allele, and by a
mutation in the S. cerevisiae SPT3 gene (42). These mutations
alter the interaction between TBP and the SAGA histone
acetyltransferase complex (17). High-level expression of TFIIA
most likely suppresses these mutations by assisting the TBP-
TATA interaction in the context of a repressing chromatin
structure. Therefore, TFIIA can lessen the effects of several
types of impediments to TBP-TATA complex formation.
By searching for dominant mutations in TOA1 and TOA2
that suppress TBP-P109A, we have identiﬁed three different
regions on TFIIA that may be involved in TFIID recruitment
in vivo. Three of the TOA1 mutations, encoding the changes
T254K, T254I, and S261R, alter residues along the TFIIA-
DNA interface observed by crystallography (16, 70). Alanine
scanning mutagenesis of charged residues near these positions
caused a temperature-sensitive phenotype and a reduction in
formation of a TFIIA-TBP-DNA complex in vitro (28). Crys-
tallography of the TFIIA-TBP-TATA complex has revealed
direct contacts between DNA and the Toa1 residues Thr252,
Arg253, Lys255, Arg257, and Lys259 (16, 70). Two of these
amino acids, Arg253 and Lys255, are in a position to make
direct contacts with the phosphodiester backbone of the TATA
box (70). The T254K and T254I substitutions, isolated in our
mutant hunt, may create additional contacts between TFIIA
and the TATA box. Such interactions might be especially im-
portant contributors to the overall stability of the TFIIA-TBP-
DNA complex (72). Ser261 of Toa1 lies very near the basic
amino acids that directly contact DNA upstream of the TATA
box. Introduction of an arginine at this position might create a
novel interaction between TFIIA and DNA. Two other muta-
tions identiﬁed in our screen, encoding Toa1-Q280R and
Toa2-E88K, also introduce basic amino acids in the proximity
of DNA 59 to the TATA box (Fig. 4A), and may further extend
the TFIIA-DNA interface. In agreement with these predic-
tions, TFIIA derivatives containing the Toa1-T254K, Toa1-
T254I, and Toa1-S261R subunits increased the formation
and/or stability of TFIIA-TBP-DNA complexes in vitro (Fig.
4B and C).
In contrast to the behavior of the Ser261 and Thr254 re-
placements in Toa1, we identiﬁed three other TFIIA mutants,
Toa1-D226V, Toa2-G30E, and Toa2-G30R, that signiﬁcantly
affected the TBP mutant phenotypes in vivo but did not de-
tectably enhance TFIIA-TBP-DNA complex formation in
vitro. Analysis of a Toa1 mutant protein in which residues 217
to 240 had been deleted demonstrated that this region is im-
portant for interacting with TBP (28). However, on one of the
two reported TFIIA-TBP-DNA crystal structures, aspartic acid
226 is not in direct contact with TBP but rather lies in a highly
acidic, solvent-exposed region (15, 16). On the other crystal
structure, the positions of Asp226 and adjacent amino acids
could not be determined accurately, indicating ﬂexibility in this
region (70). Our results suggest that this region may represent
an important interaction site for factors that regulate TFIIA
activity. Interestingly, three serine residues near Asp226, in-
cluding Ser225, have been recently implicated in phosphoryla-
tion of Toa1 (64). Phosphorylation of TFIIA increases its abil-
ity to support TFIIA-TBP-TATA complex formation (64). Our
genetic studies demonstrated that the Toa1-D226V mutant
strongly suppressed the TBP-P109A mutant but signiﬁcantly
enhanced the Ino
2 phenotype of the TBP-N159D mutant. The
latter result is in excellent agreement with the proximity of
Asp226 to the presumed sites of phosphorylation. If the
D226V change interferes with phosphorylation of Toa1, then
the activity of TFIIA in TBP recruitment will be reduced,
further compromising TBP-TATA complex formation. The ba-
sis for suppression of TBP-P109A by Toa1-D226V is less easily
explained by this model. By many other criteria, TBP-P109A
and TBP-N159D behave similarly (3, 60). However, substitu-
tion of a critical proline residue in TBP that is important for
DNA binding and that lies near a TFIIA contact point (16, 70)
may signiﬁcantly alter the conformation of TBP in such a way
that it can be suppressed by the mutant TFIIA. This conclusion
is consistent with the temperature-sensitive growth properties
of TBP-P109A mutant strains.
Despite an extensive search for TOA2 mutations that sup-
press the TBP mutants, we identiﬁed nine mutations that
change the same amino acid in the protein, Gly30. This residue
lies at the tip of the four-helix bundle domain, within a turn
that connects the two alpha helices of Toa2 (16, 70). A re-
placement of glycine at this position with either glutamic acid
or arginine very likely affects the structure of the four-helix
bundle domain. Previous studies demonstrated that the four-
helix bundle domain is important for the coactivation proper-
ties of TFIIA in vitro (40). Our data provide strong support for
this conclusion in vivo. Interestingly, alanine scanning mu-
tagenesis of TOA2 generated only three temperature-sensitive
alleles, two of which affect residues near glycine 30 (28). In
agreement with the inability of the Toa2-G30E and Toa2-
G30R proteins to enhance TFIIA-TBP-TATA complex forma-
tion in vitro (Fig. 4B and C), Kang et al. (28) concluded that
the temperature-sensitive toa2 mutants were defective in a
function other than TBP binding, TFIIA-TBP-TATA complex
assembly, or subunit association.
The promoter-speciﬁc effects of the activation- and DNA
binding-defective TBP mutants, coupled with the suppression
of these mutants by high levels of TFIIA, suggested to us that
the requirement for TFIIA may vary at different promoters.
Indeed, depletion of TFIIA dramatically reduced activation of
INO1, GAL1, and GAL10 but had no effect on activation of
HIS4 or CUP1. These results complement those of Ozer et al.
(49), who recently reported a temperature-sensitive toa2 mu-
tation that reduced TBP binding and affected the transcription
of a distinct set of genes, including some involved in cell cycle
progression. A defect in GAL1 activation was also observed
with this toa2 mutant; however, the magnitude of the effect,
about twofold, was signiﬁcantly smaller than what we observed
by reducing TFIIA levels. This difference may be due to resid-
ual function of the Toa2 mutant protein under the conditions
tested. This complexity, which is inherent to mutant analyses of
essential genes, can be avoided by using depletion strategies
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Ozer et al. (49), we observed no effect on CUP1 activation fol-
lowing Toa1 depletion. Moreover, the TBP-P109A and TBP-
N159D mutant proteins supported wild-type levels of CUP1
induction. These results are in apparent conﬂict with an earlier
report of a TBP mutant, N2-1, which is unable to bind TFIIA
in vitro and which causes a signiﬁcant reduction in CUP1
activation (66). One explanation for this discrepancy is that
N2-1 may be impaired for functions other than TFIIA binding
and that these functions are critical for CUP1 activation. In-
terestingly, artiﬁcial recruitment of TFIIA by fusing N2-1 with
Toa2 only partially rescued the GAL gene activation defect of
the TBP mutant (66).
By depleting TFIIA to very low levels and then exposing the
cells to conditions for gene activation, we have determined the
relative need for TFIIA in the induction of various genes.
Previous studies involving conditional depletion of TFIIA fo-
cused on genes that were constitutively transcribed and dem-
onstrated a general requirement for TFIIA in maintaining the
expression of these genes (28). By ﬁrst activating INO1 and
HIS4 and then depleting TFIIA levels, we have found a similar
overall requirement for TFIIA in maintaining the transcription
of these genes (39). Moreover, the rates at which these
mRNAs decline following TFIIA depletion are similar. These
results are in dramatic contrast to the promoter-speciﬁc effects
in gene induction we have observed (Fig. 6 and 7). Together,
our ﬁndings suggest that the requirement for TFIIA in the
establishment of a preinitiation complex is highly variable; but
once formed, the activated transcription complex remains
TFIIA dependent to similar degrees at different genes. How-
ever, in the absence of more-direct biochemical support, our
data can also be explained by a model in which the earliest
rounds of transcription reinitiation at promoters such as INO1
are particularly dependent on TFIIA.
By regulating transcription in a gene-speciﬁc manner, TFIIA
behaves similarly to several other generally acting transcription
factors. In a recent genome-wide expression study, important
components of the Srb-mediator, Swi-Snf, TFIID, and SAGA
complexes were shown to affect only fractions of the RNA
polymerase II-transcribed genes in yeast (24). What is the basis
for the promoter speciﬁcity of TFIIA function? In keeping with
the multiple functions of TFIIA, a number of causes are prob-
able. The severity of the activation defect associated with
certain TFIIA mutants depends signiﬁcantly on the activator
proteins involved (49). These mutants are also sensitive to
differences in promoter structure in vivo (49). For some pro-
moters, this effect of promoter structure most likely stems from
the action of additional regulatory factors. For example, by
selecting for genetic suppressors of TBP-P109A, we have im-
plicated the Opi1 repressor and the Snf1 kinase pathway in the
regulation of PIC assembly at INO1 (60). These ﬁndings sug-
gest that TFIID recruitment may be impeded, directly or in-
directly, by gene speciﬁc-repressor proteins or chromatin at
INO1. The apparent lack of a TFIIA requirement at certain
promoters, such as CUP1, may indicate that redundant mech-
anisms contribute to activation. CUP1 is a particularly inter-
esting case because activation of this gene is unaffected by
conditions that disfavor holoenzyme (35, 44) or TFIID recruit-
ment (Fig. 7). Perhaps either mode of activation sufﬁces for
this promoter, or perhaps this promoter utilizes an entirely
different mechanism of activation. Genetic studies on the RNA
polymerase II general transcription factors should continue to
elucidate the many and diverse strategies used for transcrip-
tional activation in vivo.
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